Biodelivery Sciences International Inc (BDSI) Form 4 Filed by Broadfin Healthcare Master Fund Ltd and 2 Others, Feb 15, 2022
SEC Form 4 · No Market Transaction
Conversion
Conversion of derivative securities.
Reporting Owners
Director
Director
Director
TXN 2022-02-11
·
FILED 2022-02-15
Equity Position
7.59M sh
5,166,173 → 7,588,395
Equity Change
+46.9%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owners
| Name | Relationship |
|---|---|
| Broadfin Healthcare Master Fund Ltd CIK 0001511900 |
Director
|
| Kevin Kotler CIK 0001601692 |
Director
|
| Broadfin Capital, LLC CIK 0001511901 |
Director
|
Broadfin Healthcare Master Fund Ltd at Biodelivery Sciences International Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Biodelivery Sciences International Inc
| 2022-03-22 | Gift/Other | — | View |
| 2022-01-31 | Exercise | — | View |
| 2021-11-22 | Buy | +$306,000 | View |
| 2021-11-15 | Buy | +$320,000 | View |
| 2021-11-09 | Buy | +$894,566 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1 | 2022-02-11 | C - Conversion | 2,422,222 A | $1.80 | +$4,360,000 | 7,588,395 | Indirect |
Derivative Securities Transactions
Footnotes (2)
- F1
- 6,822,911 shares of Common Stock are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC, and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Broadfin Healthcare Master Fund, Ltd., Broadfin Capital, LLC, and Kevin Kotler affirmatively (i) disclaim beneficial ownership of the reportable securities, (ii) states that this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 ("Section 16") of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, except to the extent of their pecuniary interest therein, and (iii) disclaim being a "group" for purposes of Section 16. Show more
- F2
- The securities may not be converted if, after such conversion, the Reporting Person would beneficially own, as determined in accordance with Section 13(d) of the Act, more than 9.98% of the Common Stock outstanding immediately after giving effect to such conversion. The securities do not have an expiration date, but the issuer may force conversion of the securities, subject to certain limitations. Show more
Related filings at Biodelivery Sciences International Inc
Other insiders at Biodelivery Sciences International Inc
GET /v1/forms/4/0001103021-22-000047
API docs
View Original SEC Filing